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AnticonvulsantAbstract A series of various Schiff’s and Mannich base derivatives (N1–2 & ND1–6) of Lamotri-
gine with isatin and substituted isatin were synthesized to get more potent anticonvulsant agents. The
starting material for the synthesis of various new Schiff’s and Mannich base derivatives was isatin
(1H-indole- 2, 3-dione) which in turn was prepared from substituted isonitrosoacetanilide using
aniline. Lamotrigine reacts with isatin & substituted isatin gave Schiff’s bases (N1–2) which on reac-
tion with various secondary amines (dimethylamine, diethylamine, morpholine) produced Mannich
bases (ND1–6). The structures of newly synthesized compounds were characterized by using TLC,
UV, FT-IR, 1HNMR and studied for their anticonvulsant activity. Anticonvulsant activity of all
the derivatives was evaluated by MES method using phenobarbitone sodium & Lamotrigine as
standard drugs and % reduction of time spent by animals in extension, ﬂexion, clonus, and stupor
phase were noted. Compounds ND-4 and ND-6 showed signiﬁcant anticonvulsant activity when
compared with that of standard drugs. The remaining all compounds show moderate activity.
Biological activity data of the synthesized derivatives revealed that, the synthesized derivatives are
good anticonvulsant agents as compared to Lamotrigine.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Lamotrigine is a member of drug class of phenyltriazine, used
for the adjunctive treatment of partial seizures in epilepsy and
generalized seizures of Lennox–Gastaut syndrome (Lebre
et al., 2003; Qian et al., 2009; Sagud et al., 2008; Calabrese
et al., 1999). It is also used for the maintenance treatment
of bipolar I disorder and depression. (Barbee and Jamhour,
Synthesis, characterization and biological behavior of some Schiff’s and Mannich S1852002; Botts and Raskind, 1999). Isatin is an endogenous
molecule identiﬁed in human beings which has anticonvulsant
(Bhattacharya and Chakrobarti,1998; Gursoy and Karali,
1996; Popp and Donogn, 1979), antimicrobial, tuberculostatic,
analgesic and various other pharmacological activities. Exten-
sive literature review has been made regarding the activities of
the isatin, especially for its anticonvulsant, antimicrobial, anal-
gesic and anti-inﬂammatory activities (Silva et al., 2001;
Sridhar et al., 2001). Schiff’s bases and Mannich bases of isatin
(Pandeya et al., 2000) were reported to possess anticonvulsant
activity and various other pharmacological activities (Aboul-
fadl and Aboul-wafa, 2010; Agarwal et al., 2006; Chakraborty
et al., 2010; Liu et al., 2005; Pandeya et al., 2002; Verma
et al.,2004).
Literature review indicates that, Lamotrigine is less potent
and shows side effects. In order to increase the potency
and reduce the side effects of Lamotrigine, we have consid-
ered isatin as one of the conjugate which can be coupled
with Lamotrigine due to its structural similarities with
already known anticonvulsants such as Mephobarbital, Phe-
nytoin. Herein we report the synthesis, characterization and
in vivo anticonvulsant activity of Lamotrigine derivatives
(Scheme 1).2. Materials and methods
2.1. Materials
All the reagents used for synthesis were obtained from Sigma
Aldrich and Loba Chem Ltd. (India). All the solvents used
in these studies were dried and distilled before use. Melting
points were determined by using Veego digital melting point
apparatus (VMP-PM, 32/1104) and are uncorrected. All the
reactions were monitored by thin layer chromatography
(TLC) using Silica gel G (60 mesh). The solvent system used
includes Acetone: Toluene: Ammonia (7:3:1). The IR spectra
(KBr) were recorded on a FTIR spectrophotometer with Dif-
fuse Reﬂectance attachment (Shimadzu 8400S). UV studies
were carried out on a UV Visible spectrophotometer (Shima-
dzu 1700) and the kmax of the respective synthesized com-
pounds was determined using ethanol as the solvent. 1H
NMR spectra were recorded on NMR spectrometer (Varian
Mercury YH 300) with DMSO as a solvent with TMS as an
internal standard.NC: Distill water, Phen: Phenobarbitone so
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Scheme 1 Scheme of synthesis. Step 1: Synthesis of Schiff’s bases (im
Mannich bases of synthesized Schiff’s bases.2.2. Methods
2.2.1. Synthesis of 3,30{[6-(2,3-dichlorophenyl)-1,2,4-triazine-
3,5 diyl]dinitrolo}bis-(1,3-dihydro-2H-indol-2-one) N-1
To 20 ml of hot ethanol, 0.735 gm (0.005 mol) of isatin and
0.640 gm (0.0025 mol) of Lamotrigine were dissolved. To this
mixture 1.0 ml of glacial acetic acid was added. The reaction
mixture was then reﬂuxed on a water bath in a 250 ml round
bottomed ﬂask for 8 h. Completion of the reaction was moni-
tored by TLC. The mixture was allowed to stand for 24 h at
room temperature. The product was collected and recrystal-
lized with ethanol-chloroform mixture.
N-1: Yield: 76%; m.p.: 145–148 C. IR (KBr) (cm1): 3444
(NH), 3088 (Ar-CH), 1731 (C‚O), 1616(C‚N), 771 (C-Cl);
1H NMR (DMSO) d (ppm): 6.6–7.7 (m, Ar-H), 10.29 (s, 2H,
NH); Anal. Calcd for C25H13Cl2N7O: C, 58.38; H, 2.55; N,
19.06; Found: C, 58.31; H, 2.48; N, 19.01%.
2.2.2. Synthesis of 3,30{[6-(2,3-dichlorophenyl)-1,2,4-triazine-
3,5-diyl]dinitrolo}bis-(5-chloro-1,3-dihydro-2H-indol-2-one) N-
2
N-2 obtained from 5-choroisatin (0.90 gm, 0.005 mol) under
the same conditions as describe above for N-1.
N-2: Yield: 73%; m.p.: 162–165 C. IR (KBr) (cm1): 3309
(NH), 3070 (Ar-CH), 1741 (C‚O), 1612 (C‚N), 798 (C-Cl);
1H NMR (DMSO) d (ppm): 6.9–7.9 (m, 9H, Ar-H), 10.29 (s,
2H, NH); Anal. Calcd for C25H11Cl4N7O: C, 51.49; H, 1.90;
N, 16.81; Found: C, 51.35; H, 1.78; N, 16.75%.
2.2.3. Synthesis of 3,30{[6-(2,3-dichlorophenyl)-1,2,4-triazine-
3,5-diyl]dinitrolo}bis-{1-[(dimethylamino)methyl]1,3-dihydro-
2H-indol-2-one} ND-1
A slurry consisting of the N-1 (0.0025 mol), THF (5 ml) and
37% formalin (2 ml) was made. To this dimethylamine
(0.005 mol) was added drop wise with cooling and shaking.
The reaction mixture was allowed to stand at room tempera-
ture for 1 h with occasional shaking after which it was warmed
on a steam bath for 15 min. At the end of the period the con-
tents were cooled and the product was obtained, which was
further recrystallized from ethanol.
ND-1: Yield: 80%; m.p.: 94–97 C. IR (KBr) (cm1): 2887
(N-CH2-N), 3064 (Ar-CH), 1735 (C‚O), 1610 (C‚N), 757
(C-Cl); 1H NMR (CDCl3) d (ppm): 2.19 (s, 12H, CH3), 4.00
(s, 4H, N-CH2-N), 6.6–8.0 (m, 11H, Ar-H); Anal. Calcd fordium, Lamo: Lamotrigine 
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ines) from Lamotrigine and substituted isatin. Step 2: Synthesis of
Table 1 A series of compounds used for synthesis.
Compound Code R1 R2
N-1 H –
N-2 Cl –
ND-1 H –N(CH3)2
ND-2 Cl –N(CH3)2
ND-3 H –N(C2H5)2
ND-4 Cl –N(C2H5)2
ND-5 H –NC4H8O
ND-6 Cl –NC4H8O
S186 A.A. Kulkarni et al.C31H27Cl2N9O2: C, 59.24; H, 4.33; N, 20.06; Found: C, 59.19;
H, 4.28; N, 19.96%.
2.2.4. Synthesis of 3,30{[6-(2,3-dichlorophenyl)-1,2,4-triazine-
3,5-diyl]dinitrolo}bis-{5-chloro-1-[(dimethylamino)methyl]-
1,3-dihydro-2H-indol-2-one} ND-2
ND-2 obtained by using N-2 (0.0025 mol) under the same con-
ditions as describe above for ND-1.
ND-2: Yield: 75%; m.p.: 103–106 C; IR (KBr) (cm1):
2840 (N- CH2-N), 3072 (Ar-CH), 1742 (C‚O), 1608
(C‚N), 725 (C-Cl), 1H NMR (CDCl3) d (ppm): 2.34 (s,
12H, CH3), 3.97 (s, 4H, N-CH2-N), 6.7–7.6 (m, 9H, Ar-H);
Anal. Calcd for C31H25Cl4N9O2: C, 53.39; H, 3.61; N, 18.08;
Found: C, 53.25; H, 3.49; N, 18.06%.
2.2.5. Synthesis of 3,30{[6-(2,3-dichlorophenyl)-1,2,4-triazine-
3,5-diyl]dinitrolo}bis-{1-[(diethylamino)methyl]-1,3-dihydro-
2H-indol-2-one} ND-3
A slurry consisting of the N-1 (0.0025 mol), THF (5 ml) and
37% formalin (2 ml) was made. To this diethylamine
(0.005 mol) was added drop wise with cooling and shaking.
The reaction mixture was allowed to stand at room tempera-
ture for 1 h with occasional shaking after which it was warmed
on a steam bath for 15 min. At the end of the period the con-
tents were cooled and the product was obtained, which was
further recrystallized from ethanol.
ND-3: Yield: 66%; m.p.: 68–71 C; IR (KBr) (cm1): 2813
(N-CH2- N), 3058 (Ar-CH), 1730 (C‚O), 1614 (C‚N), 767
(C-Cl); 1H NMR (CDCl3) d (ppm): 1.08 (q, 12H, CH3), 2.35
(q, 8H, CH2), 4.06 (s, 4H, N-CH2-N), 6.7–7.9 (m, 11H,Table 2 Mean of the time spent by animals in extension, ﬂexion, cl
Treatment Mean of time spent by 6 animals
Extension Flex
Negative control 17.63 ± 1.47 16.6
Phenobarbitone sodium 8.51 ± 1.61 4.26
Lamotrigine 8.69 ± 0.76 5.03
N-1 13.28 ± 1.68 12.9
N-2 11.65 ± 2.36 11.0
ND-1 9.47 ± 1.19 5.80
ND-2 9.64 ± 1.38 7.64
ND-3 11.00 ± 0.67 7.97
ND-4 8.44 ± 0.83 4.89
ND-5 11.12 ± 1.25 10.1
ND-6 8.63 ± 1.38 5.07
n=mean of six determinations.Ar-H); Anal. Calcd for C35H35Cl2N9O2: C, 69.40; H, 5.15;
N, 18.41; Found: C, 69.19; H, 5.10; N, 18.36%.
2.2.6. Synthesis of 3,30{[6-(2,3-dichlorophenyl)-1,2,4-triazine-
3,5-diyl]dinitrolo}bis-{5-chloro-1-[(diethylamino)methyl]-1,3-
dihydro-2H-indol-2-one} ND-4
ND-4 obtained from N-2 (0.0025 mol) under the same condi-
tions as describe above for ND-3.
ND-4: Yield: 70%; m.p.: 84–87 C; IR (KBr) (cm1): 2868
(N-CH2-N), 3062 (Ar-CH), 1735 (C‚O), 1611 (C‚N), 760
(C-Cl); 1H NMR (CDCl3) d (ppm): 1.12 (q, 12H, CH3), 2.51
(q, 8H, CH2), 3.92 (s, 4H, N-CH2-N), 6.8–7.9 (m, 9H, Ar-
H); Anal. Calcd for C35H33Cl4N9O2: C, 55.79; H, 4.41; N,
18.82; Found: C, 55.58; H, 4.36; N, 18.75%.
2.2.7. Synthesis of 3,30{[6-(2,3-dichlorophenyl)-1,2,4-triazine-
3,5-diyl]dinitrolo}bis-[1-(morpholinomethyl)1,3-dihydro-2H-
indol-2-one] ND-5
A slurry consisting of the N-1 (0.0025 mol), THF (5 ml) and
37% formalin (2 ml) was made. To this morpholine
(0.005 mol) was added drop wise with cooling and shaking.
The reaction mixture was allowed to stand at room tempera-
ture for 1 h with occasional shaking after which it was warmed
on a steam bath for 15 min. At the end of the period the con-
tents were cooled and the product was obtained, which was
further recrystallized from ethanol.
ND-5: Yield: 86%; m.p.: 101–104 C; IR (KBr) (cm1):
2854 (N-CH2-N), 3039 (Ar-CH), 1735 (C‚O), 1609
(C = N), 765 (C-Cl); 1H NMR (CDCl3) d (ppm): 2.61–2.64
(q, 8H, CH2), 3.5–3.7 (q, 8H, CH2), 4.45 (s, 4H, N-CH2-N),
7.0–7.6 (m, 11H, Ar-H); Anal. Calcd for C35H31Cl2N9O4: C,
58.99; H, 4.38; N, 17.69; Found: C, 58.86; H, 4.36; N, 17.65%.
2.2.8. Synthesis of 3,30{[6-(2,3-dichlorophenyl)-1,2,4-triazine-
3,5-diyl]dinitrolo}bis-[5-chloro-1-(morpholinomethyl)1,3-
dihydro-2H-indol-2-one] ND-6
ND-6 obtained from N-2 (0.0025 mol) under the same condi-
tions as describe above for ND-5.
ND-6: Yield: 83%; m.p.: 108–111 C; IR (KBr) (cm1):
2785 (N-CH2-N), 3097(Ar-CH), 1743(C‚O), 1650 (C‚N),
790 (C-Cl); 1H ]NMR (CDCl3) d (ppm): 2.54–2.58 (q, 8H,
CH2), 3.48–3.60 (q, 8H, CH2), 4.23 (s, 4H, N-CH2-N), 6.8–
7.5 (m, 9H, Ar-H); Anal. Calcd for C35H29Cl4N9O4: C,
53.79; H, 3.74; N, 16.13; Found: C, 53.58; H, 3.66; N, 16.09%.onus, stupor phase.
in
ion Clonus Stupor
8 ± 1.13 23.50 ± 1.81 24.03 ± 1.32
± 0.61 6.87 ± 1.03 7.55 ± 1.45
± 0.53 9.17 ± 1.07 8.38 ± 0.75
2 ± 1.62 16.83 ± 2.46 17.84 ± 1.89
4 ± 1.81 16.21 ± 3.13 17.19 ± 1.54
± 0.80 9.64 ± 1.35 8.63 ± 1.12
± 0.94 13.66 ± 2.13 15.35 ± 1.40
± 0.76 14.04 ± 1.35 15.79 ± 1.68
± 0.67 9.26 ± 1.20 7.26 ± 1.44
9 ± 1.82 15.57 ± 3.24 17.02 ± 1.98
± 0.57 9.53 ± 1.14 8.21 ± 1.17
Table 3 Showing (%) reduction of time spent in various phases of convulsions by treated animals (When compared with solvent
treated groups).
Treatment % reduction of time spent by animals in
Extension Flexion Clonus Stupor
Negative control 100 100 100 100
Phenobarbitone sodium 48.26 25.53 29.23 31.41
Lamotrigine 49.29 30.15 39.02 34.87
N-1 75.32 77.45 71.61 74.24
N-2 66.08 66.18 68.97 71.53
ND-1 53.71 34.77 41.02 35.91
ND-2 54.67 45.80 58.12 63.87
ND-3 62.39 47.78 59.74 65.70
ND-4 47.87 29.31 39.40 30.21
ND-5 63.07 61.09 66.25 70.82
ND-6 48.95 30.39 40.55 34.16
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3.1. General
Anticonvulsant activity of Lamotrigine derivatives was tested
by Maximal the Electroshock Method (MES) (DYIPSR/
IAEC/10–11/P-23). Epilepsy resembling human epileptic types
can be induced in small laboratory animals to screen/evaluate
anticonvulsant activity of newly synthesized compoundsStep 1: Synthesis of Schiff’s bases (imines) from L
N
H
O
O
R1
2
Cl
Cl
N
N
N 2N2
+ GAA
Ethanol
I1-2 Lamotrigine
Step 2: Synthesis of Mannich bases of synthesized
Cl
Cl
NN
N
N
N
N
H
R1
NH
O
R1
O
i,ii
HCHO,T
            N1-2
Where,
i = Ethanol, GAA(Glacial Acetic 
ii = THF, HCHO, (Dimethylamin
R1 = -H, -Cl
R2= -N(CH3)2 , -N(C2H5)2, -N(mo
H NH
Graph 1 Mean of time spent by animals in(Kaminski et al., 2008; Oja et al., 1983). Present study has been
carried out by maximal electroshock (MES) convulsions mod-
el, which clinically resembles human grand-mal epilepsy. When
a stimulus (electric) of speciﬁed strength is applied using
appropriate electrodes to the test animals, the animals exhibit
different phases of convulsions, Such as extension, ﬂexion, clo-
nus, and stupor. The animals may survive/die during or after
the shock. During the experiment, time spent by animals in
various phases of the convulsion was recorded (see Table 1).amotrigine & substituted isatin. 
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Groups
EXTENSION
FLEXION
CLONUS
STUPOR
n = mean of six determinations 
NC: Distill water, Phen: Phenobarbitone sodium, Lamo: Lamotrigine 
Negative control: Distill water; Positive control: Phenobarbitone sodium, Lamotrigine  
One way ANOVA followed by paired‘t’ test is applied for statistical analysis *p<0.05 
and **p<0.01 when compared with negative control.
Graph 2 Showing (%) reduction of time spent in various phases of convulsions by treated animals.
S188 A.A. Kulkarni et al.3.2. Procedure
Either sex, 3–4 months, healthy (250–300 gm) albino rats
(wistar), overnight fasted were randomly assigned to 10 groups
(n= 6), weighed and marked. Group-I animals received a
solution in which the sample prepared was given by oral route
(Blank/controlled group). Group-II animals received Pheno-
barbitone sodium (30 mg/kg p.o.) and Lamotrigine (10 mg/
kg i.p.). (Reference/standard group). Group III–Group X
received the sample in the dose of 10 mg/kg by i.p. route. After
30 min of drug treatment a stimulus of 130 mA for 0.2 s was
delivered through electrodes (pinna) using electro convulsom-
eter (INCO India) to each animal. Immediately, time spent
by the animal in extension, ﬂexion, clonus and stupor was tab-
ulated Table 2 (mean ± SEM). Recovery/death following the
various phases of convulsions was also tabulated.
4. Results and discussion
The main aim of the present work was to synthesize some new
series of Schiff’s and Mannich base derivatives. The structures
of all the synthesized compounds were conﬁrmed on the basis
of TLC, UV, FT-IR and 1H NMR spectra. All the compounds
were screened for anticonvulsant activity using MES method.
The anticonvulsant evaluations of synthesized compounds
were done in rat at 10 mg kg1 by i.p. route. Phenobarbitone
sodium and Lamotrigine were employed as standard drugs
and % reduction of time spent by animals in extension, ﬂexion,
clonus, stupor phase was noted. Results are shown in Tables 2
and 3 and Graphs 1 and 2. Compounds ND-4 and ND-6
showed more potent anticonvulsant activity when compared
with that of the standard drug. Remaining all compounds
show moderate activity.
5. Conclusion
A series of novel Schiff’s and Mannich base derivatives were
synthesized, characterized and evaluated for their anticonvul-sant activity. The test results showed that compounds ND-4
and ND-6 exhibited signiﬁcant anticonvulsant activity while
remaining compounds showed moderate activity.Acknowledgements
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